Date:3/27/2008

P). CTP occurs naturally in humans, and when attached to a therapeutic protein, extends the time that the protein is active in the body. The potential utility of the technology has been demonstrated by Organon, a unit of Schering-Plough, which licenses the CTP technology for fertility applications only. Phase II trials of its CTP follicle stimulating hormone product (FSH-CTP) demonstrated that a single injection provides the same clinical effect as seven consecutive daily injections of standard FSH. These trials also demonstrated that attaching the CTP peptide did not affect the therapeutic activity of FSH or cause a negative immune system response. Modigene has an exclusive license from Washington University for use of CTP with all therapeutic proteins except four fertility proteins. Modigene currently has three CTP-enhanced compounds in preclinical testing and a fourth in earlier stage development. Clinical trials are expected to begin later this year.

ABOUT MODIGENE

Modigene Inc. (OTC Bulletin Board: MODG) is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins and Modigene is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on Modigene, visit http://www.modigeneinc.com.

Safe Harbor Statement: This press release contains forward-looking statements, including statements regarding the results of current studies and preclinical experiments and the effectiveness of Modigene's long-acting protein programs and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned t
'/>"/>

SOURCE Modigene Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Modigene to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Modigene to Present at the Roth 2007 New York Investor Conference
3. GeneNews announces 2007 year end results
4. China Pharma Holdings, Inc. Announces Earnings Call for Fiscal 2007 Financial Results
5. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
7. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
8. Environmental Power Announces Opening of New Corporate Headquarters in Tarrytown, NY
9. Boston Scientific Announces Schedule for ACC 2008
10. China Biologic Products Announces One of Its R&D Projects Has Been Listed In National Torch Plan
11. Medivation Announces Senior Management Promotions